Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMT-28 in Maintenance of Sinus Rhythm After Electrical Cardioversion in Persistent Atrial Fibrillation
NCT03906799Phase 2Completed
- Sponsor
- OMEICOS Therapeutics
- Start
- Mar 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of OMT-28 in persistent atrial fibrillation (PersAF) (4 arms), sponsored by OMEICOS Therapeutics. Primary endpoint: Assessment of AF Burden After OMT-28 Administration up to 4.5 months. Started Mar 2019; status: completed.
02
Drugs
OMT-28
03
Conditions
persistent atrial fibrillation (PersAF)
Beyond the preview
Go deeper on NCT03906799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03906799.